Genovate Biotechnology Co., Ltd. (TPEX:4130)
Taiwan · Delayed Price · Currency is TWD 26.60
+0.75 (2.90%)
May 29, 2026, 1:30 PM CST
Genovate Biotechnology Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -9.17 | 11.68 | 25.7 | 29.33 | -12.32 | 0.37 |
Depreciation & Amortization | 35.45 | 36.19 | 35.73 | 35.14 | 35.08 | 34.74 |
Other Amortization | 2.56 | 2.56 | 2.1 | 1.41 | 1 | 1.08 |
Loss (Gain) From Sale of Investments | -0.55 | -0.49 | -0.47 | -0.45 | -0.07 | - |
Loss (Gain) on Equity Investments | 2.27 | 2.26 | 0.96 | 3.88 | -0.29 | -0.14 |
Stock-Based Compensation | 10.69 | - | - | - | 11.7 | - |
Provision & Write-off of Bad Debts | -0 | -0 | -0 | -0.01 | -0 | 0 |
Other Operating Activities | -7.73 | -4.16 | 2.88 | -2.34 | -0.58 | 1.49 |
Change in Accounts Receivable | 14.71 | 1.76 | -2.95 | 13.13 | 0.24 | -29.87 |
Change in Inventory | -7.37 | 2.05 | -6.23 | 6.22 | -5.92 | -0.3 |
Change in Accounts Payable | -2.59 | -10.32 | 7.42 | -12.93 | 10.92 | 11.65 |
Change in Unearned Revenue | 0.12 | -0.17 | -2.94 | 0.17 | 0.71 | 0.11 |
Change in Other Net Operating Assets | -34.55 | 9.5 | -2.6 | 26.04 | -32.04 | -23.38 |
Operating Cash Flow | 1.81 | 43.79 | 55.11 | 84.78 | 1.51 | -17.26 |
Operating Cash Flow Growth | -98.25% | -20.54% | -35.00% | 5514.70% | - | - |
Capital Expenditures | -38.1 | -55.73 | -30.78 | -27.98 | -23.55 | -17.96 |
Sale (Purchase) of Intangibles | -4.01 | -5.69 | -0.6 | -5.37 | -0.47 | -0.17 |
Investment in Securities | -429.15 | -22.22 | 55.55 | -41.15 | 17.03 | 57.12 |
Other Investing Activities | -0.62 | -0.7 | 5.46 | -4.2 | 1.23 | -2.09 |
Investing Cash Flow | -471.89 | -84.33 | 29.64 | -78.68 | -5.75 | 36.9 |
Long-Term Debt Repaid | - | -0.92 | -1.05 | -1.26 | -1.22 | -1.23 |
Net Debt Issued (Repaid) | -0.98 | -0.92 | -1.05 | -1.26 | -1.22 | -1.23 |
Issuance of Common Stock | 640.18 | - | - | - | 38.88 | - |
Repurchase of Common Stock | - | - | -25.72 | - | - | - |
Common Dividends Paid | -11.15 | -11.15 | -16.41 | -19.14 | -37.76 | -43.36 |
Other Financing Activities | 0.04 | 0.05 | -0.01 | 0.16 | 0.06 | 0.18 |
Financing Cash Flow | 628.09 | -12.02 | -43.18 | -20.23 | -0.04 | -44.41 |
Net Cash Flow | 158.01 | -52.56 | 41.57 | -14.13 | -4.28 | -24.77 |
Free Cash Flow | -36.29 | -11.94 | 24.34 | 56.81 | -22.04 | -35.22 |
Free Cash Flow Growth | - | - | -57.16% | - | - | - |
Free Cash Flow Margin | -7.70% | -2.42% | 4.76% | 10.75% | -5.02% | -8.11% |
Free Cash Flow Per Share | -0.32 | -0.10 | 0.21 | 0.49 | -0.19 | -0.31 |
Cash Interest Paid | 0.68 | 0.68 | 0.52 | 0.27 | 0.28 | 0.25 |
Cash Income Tax Paid | 5.98 | 5.98 | 2.34 | 3.39 | 3.45 | 1.73 |
Levered Free Cash Flow | -62.2 | -23.67 | 27.83 | 58.76 | -3.69 | -23.57 |
Unlevered Free Cash Flow | -61.81 | -23.24 | 28.15 | 58.92 | -3.51 | -23.41 |
Change in Working Capital | -31.71 | -4.25 | -11.78 | 17.82 | -33.02 | -54.8 |